Home › NCT06772675
Vancomycin Reduction Practices (VRP) in the NICU
Implementing Vancomycin Reducing Practices (VRP) in Preterm Infants
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Level III NICU * Affiliated with Kaiser Permanente Northern California (KPNC) or Children's Hospital of Philadelphia Newborn Care Network (CNBCN) * Recruited by study team Exclusion Criteria: * Site not recruited for the study
About the study
This multi-center, cluster randomized study aimed at improving implementation of vancomycin reducing practices (VRP) in neonatal intensive care units (NICUs). Sites will be recruited and randomized to receive either external facilitation or no external facilitation to assess the effect on center-level fidelity to the core components of VRP implementation. Interventions available to both study arms are directed at hospital staff and includes identification of local champions, educational outreach, unit-level audit \& feedback, and use of a clinical decision support tool.
What is being tested
- External Facilitation (behavioral)
Sponsor: Children's Hospital of Philadelphia · Participants: 13 · Started: Jun 2, 2025
Contact the study team
- Kayla Gilpin · Phone: 215-573-3976
- Morgan Gabbert · Phone: 267-233-3150
Official record on ClinicalTrials.gov — NCT06772675
Locations in the U.S.
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.